NO323698B1 - C-aryl-glukosid-SGLT2-inhibitorer, farmasoytiske blandinger og kombinasjoner inneholdende disse, anvendelse av disse for fremstilling av farmasoytisk preparat til behandling samt et mellomprodukt for fremstilling. - Google Patents

C-aryl-glukosid-SGLT2-inhibitorer, farmasoytiske blandinger og kombinasjoner inneholdende disse, anvendelse av disse for fremstilling av farmasoytisk preparat til behandling samt et mellomprodukt for fremstilling. Download PDF

Info

Publication number: NO323698B1
Authority: NO; Norway
Prior art keywords: agent; inhibitor; alkyl; mmol; compounds
Prior art date: 1999-10-12

Application number

NO20021721A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021721L (no

NO20021721D0 (no

Inventor

Philip M Sher

William N Washburn

Bruce Ellsworth

Wei Meng

Gang Wu

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-12

Filing date

2002-04-11

Publication date

2007-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26855382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323698(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-11 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-04-11 Publication of NO20021721D0 publication Critical patent/NO20021721D0/no

2002-06-10 Publication of NO20021721L publication Critical patent/NO20021721L/no

2007-06-25 Publication of NO323698B1 publication Critical patent/NO323698B1/no

Links

229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title claims abstract description 20
238000002360 preparation method Methods 0.000 title claims description 15
239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
239000008194 pharmaceutical composition Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 165
125000000217 alkyl group Chemical group 0.000 claims abstract description 39
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 33
239000003472 antidiabetic agent Substances 0.000 claims abstract description 29
229940125708 antidiabetic agent Drugs 0.000 claims abstract description 26
150000002367 halogens Chemical class 0.000 claims abstract description 26
229910052736 halogen Inorganic materials 0.000 claims abstract description 24
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
239000001257 hydrogen Substances 0.000 claims abstract description 17
229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
229910052717 sulfur Inorganic materials 0.000 claims abstract description 10
-1 -OCHF2 Chemical group 0.000 claims description 72
239000003112 inhibitor Substances 0.000 claims description 56
239000000203 mixture Substances 0.000 claims description 49
239000003524 antilipemic agent Substances 0.000 claims description 25
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 24
239000003795 chemical substances by application Substances 0.000 claims description 20
230000000694 effects Effects 0.000 claims description 16
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 14
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
102000004877 Insulin Human genes 0.000 claims description 12
108090001061 Insulin Proteins 0.000 claims description 12
229930182478 glucoside Natural products 0.000 claims description 12
229940125396 insulin Drugs 0.000 claims description 12
125000004093 cyano group Chemical group *C#N 0.000 claims description 11
150000002431 hydrogen Chemical class 0.000 claims description 11
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
208000002249 Diabetes Complications Diseases 0.000 claims description 9
239000000556 agonist Substances 0.000 claims description 9
239000000883 anti-obesity agent Substances 0.000 claims description 8
229940125710 antiobesity agent Drugs 0.000 claims description 8
201000001320 Atherosclerosis Diseases 0.000 claims description 7
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 7
102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims description 7
230000000879 anti-atherosclerotic effect Effects 0.000 claims description 7
150000008131 glucosides Chemical class 0.000 claims description 7
239000004059 squalene synthase inhibitor Substances 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
206010022489 Insulin Resistance Diseases 0.000 claims description 6
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 6
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 6
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 6
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 6
201000001421 hyperglycemia Diseases 0.000 claims description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 6
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 5
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 5
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 5
229940123208 Biguanide Drugs 0.000 claims description 5
102000004366 Glucosidases Human genes 0.000 claims description 5
108010056771 Glucosidases Proteins 0.000 claims description 5
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 5
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 5
229940030600 antihypertensive agent Drugs 0.000 claims description 5
239000002220 antihypertensive agent Substances 0.000 claims description 5
229940127218 antiplatelet drug Drugs 0.000 claims description 5
229960005370 atorvastatin Drugs 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 5
229960005110 cerivastatin Drugs 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
229960003765 fluvastatin Drugs 0.000 claims description 5
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 5
229960003105 metformin Drugs 0.000 claims description 5
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 5
229960001243 orlistat Drugs 0.000 claims description 5
229960002965 pravastatin Drugs 0.000 claims description 5
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 5
229960002855 simvastatin Drugs 0.000 claims description 5
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 4
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 4
229940100389 Sulfonylurea Drugs 0.000 claims description 4
125000005530 alkylenedioxy group Chemical group 0.000 claims description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 4
229960001381 glipizide Drugs 0.000 claims description 4
229960004844 lovastatin Drugs 0.000 claims description 4
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 4
229950004994 meglitinide Drugs 0.000 claims description 4
DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 4
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 4
230000001235 sensitizing effect Effects 0.000 claims description 4
102000004217 thyroid hormone receptors Human genes 0.000 claims description 4
108090000721 thyroid hormone receptors Proteins 0.000 claims description 4
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 3
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 3
ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims description 3
PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 claims description 3
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 3
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 3
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 3
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
229940086609 Lipase inhibitor Drugs 0.000 claims description 3
239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 3
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 3
208000008589 Obesity Diseases 0.000 claims description 3
229940123495 Squalene synthetase inhibitor Drugs 0.000 claims description 3
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 3
229960002632 acarbose Drugs 0.000 claims description 3
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
239000000048 adrenergic agonist Substances 0.000 claims description 3
229940125709 anorectic agent Drugs 0.000 claims description 3
239000002830 appetite depressant Substances 0.000 claims description 3
229960001761 chlorpropamide Drugs 0.000 claims description 3
229960000632 dexamfetamine Drugs 0.000 claims description 3
229940125753 fibrate Drugs 0.000 claims description 3
229960003627 gemfibrozil Drugs 0.000 claims description 3
229960000346 gliclazide Drugs 0.000 claims description 3
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 3
229960004346 glimepiride Drugs 0.000 claims description 3
208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
239000013067 intermediate product Substances 0.000 claims description 3
229960001110 miglitol Drugs 0.000 claims description 3
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims description 3
235000020824 obesity Nutrition 0.000 claims description 3
229960005095 pioglitazone Drugs 0.000 claims description 3
RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 claims description 3
229960002354 repaglinide Drugs 0.000 claims description 3
229960004586 rosiglitazone Drugs 0.000 claims description 3
229960000672 rosuvastatin Drugs 0.000 claims description 3
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 3
229940076279 serotonin Drugs 0.000 claims description 3
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 3
229960004425 sibutramine Drugs 0.000 claims description 3
150000003536 tetrazoles Chemical class 0.000 claims description 3
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 3
229960004394 topiramate Drugs 0.000 claims description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 3
229960001641 troglitazone Drugs 0.000 claims description 3
230000029663 wound healing Effects 0.000 claims description 3
LPYQDDHAJRABQA-DYESRHJHSA-N (3r)-3-[(13r)-13-hydroxy-10-oxotetradecyl]-5,7-dimethoxy-3h-2-benzofuran-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)O[C@@H]2CCCCCCCCCC(=O)CC[C@@H](C)O LPYQDDHAJRABQA-DYESRHJHSA-N 0.000 claims description 2
QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 claims description 2
NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 claims description 2
IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 claims description 2
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 claims description 2
102000003638 Glucose-6-Phosphatase Human genes 0.000 claims description 2
108010086800 Glucose-6-Phosphatase Proteins 0.000 claims description 2
208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
102000000853 LDL receptors Human genes 0.000 claims description 2
108010001831 LDL receptors Proteins 0.000 claims description 2
229940122142 Lipoxygenase inhibitor Drugs 0.000 claims description 2
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims description 2
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
229950010046 avasimibe Drugs 0.000 claims description 2
108010014210 axokine Proteins 0.000 claims description 2
210000004369 blood Anatomy 0.000 claims description 2
239000008280 blood Substances 0.000 claims description 2
MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 claims description 2
229950002397 cetilistat Drugs 0.000 claims description 2
229960001214 clofibrate Drugs 0.000 claims description 2
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 2
230000003111 delayed effect Effects 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 2
229960003638 dopamine Drugs 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
229960002297 fenofibrate Drugs 0.000 claims description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
201000008980 hyperinsulinism Diseases 0.000 claims description 2
229960003562 phentermine Drugs 0.000 claims description 2
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
229960000395 phenylpropanolamine Drugs 0.000 claims description 2
229960002797 pitavastatin Drugs 0.000 claims description 2
239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 2
ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
206010012689 Diabetic retinopathy Diseases 0.000 claims 1
102000015779 HDL Lipoproteins Human genes 0.000 claims 1
108010010234 HDL Lipoproteins Proteins 0.000 claims 1
229940122907 Phosphatase inhibitor Drugs 0.000 claims 1
102100038129 Transcription factor Dp family member 3 Human genes 0.000 claims 1
208000033679 diabetic kidney disease Diseases 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
229960000698 nateglinide Drugs 0.000 claims 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 abstract description 26
125000003118 aryl group Chemical group 0.000 abstract description 24
125000000753 cycloalkyl group Chemical group 0.000 abstract description 15
239000003814 drug Substances 0.000 abstract description 15
238000000034 method Methods 0.000 abstract description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
229940124597 therapeutic agent Drugs 0.000 abstract description 9
201000010099 disease Diseases 0.000 abstract description 6
125000000623 heterocyclic group Chemical group 0.000 abstract description 6
229910052757 nitrogen Inorganic materials 0.000 abstract description 6
125000002837 carbocyclic group Chemical group 0.000 abstract description 4
230000002401 inhibitory effect Effects 0.000 abstract description 3
125000004433 nitrogen atom Chemical group N* 0.000 abstract description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
108091006269 SLC5A2 Proteins 0.000 abstract 1
102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 183
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 139
235000019439 ethyl acetate Nutrition 0.000 description 91
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
238000006243 chemical reaction Methods 0.000 description 71
239000000243 solution Substances 0.000 description 70
239000002904 solvent Substances 0.000 description 63
239000011734 sodium Substances 0.000 description 53
239000000460 chlorine Substances 0.000 description 49
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 48
239000012267 brine Substances 0.000 description 43
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 43
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
239000000741 silica gel Substances 0.000 description 37
229910002027 silica gel Inorganic materials 0.000 description 37
239000011541 reaction mixture Substances 0.000 description 36
229920006395 saturated elastomer Polymers 0.000 description 28
238000005481 NMR spectroscopy Methods 0.000 description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
238000004128 high performance liquid chromatography Methods 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
239000008103 glucose Substances 0.000 description 25
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
239000012044 organic layer Substances 0.000 description 23
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
238000004458 analytical method Methods 0.000 description 20
238000004809 thin layer chromatography Methods 0.000 description 20
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 19
239000000725 suspension Substances 0.000 description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
238000001035 drying Methods 0.000 description 16
238000000605 extraction Methods 0.000 description 16
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
238000001514 detection method Methods 0.000 description 15
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
230000014759 maintenance of location Effects 0.000 description 15
239000007787 solid Substances 0.000 description 15
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
235000011007 phosphoric acid Nutrition 0.000 description 14
239000003054 catalyst Substances 0.000 description 13
238000004587 chromatography analysis Methods 0.000 description 13
125000001072 heteroaryl group Chemical group 0.000 description 13
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 13
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
102000001494 Sterol O-Acyltransferase Human genes 0.000 description 12
108010054082 Sterol O-acyltransferase Proteins 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
238000003756 stirring Methods 0.000 description 12
238000010792 warming Methods 0.000 description 12
NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 11
230000008878 coupling Effects 0.000 description 11
238000010168 coupling process Methods 0.000 description 11
238000005859 coupling reaction Methods 0.000 description 11
238000002953 preparative HPLC Methods 0.000 description 11
238000000746 purification Methods 0.000 description 11
125000001424 substituent group Chemical group 0.000 description 11
239000006188 syrup Substances 0.000 description 11
235000020357 syrup Nutrition 0.000 description 11
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
108091006277 SLC5A1 Proteins 0.000 description 10
102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 10
125000002252 acyl group Chemical group 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
125000003342 alkenyl group Chemical group 0.000 description 9
125000003545 alkoxy group Chemical group 0.000 description 9
125000000304 alkynyl group Chemical group 0.000 description 9
125000003710 aryl alkyl group Chemical group 0.000 description 9
239000000047 product Substances 0.000 description 9
229910052708 sodium Inorganic materials 0.000 description 9
125000004414 alkyl thio group Chemical group 0.000 description 8
239000002585 base Substances 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
238000011161 development Methods 0.000 description 8
239000002038 ethyl acetate fraction Substances 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
239000000543 intermediate Substances 0.000 description 8
239000006186 oral dosage form Substances 0.000 description 8
239000002841 Lewis acid Substances 0.000 description 7
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
229910052801 chlorine Inorganic materials 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
210000003734 kidney Anatomy 0.000 description 7
150000007517 lewis acids Chemical class 0.000 description 7
239000003921 oil Substances 0.000 description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
229940126902 Phlorizin Drugs 0.000 description 6
239000002253 acid Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 6
239000000463 material Substances 0.000 description 6
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 6
IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 6
235000019139 phlorizin Nutrition 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
210000000512 proximal kidney tubule Anatomy 0.000 description 6
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 6
102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 5
108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 5
108010078791 Carrier Proteins Proteins 0.000 description 5
108091052347 Glucose transporter family Proteins 0.000 description 5
206010018473 Glycosuria Diseases 0.000 description 5
229940123464 Thiazolidinedione Drugs 0.000 description 5
125000004450 alkenylene group Chemical group 0.000 description 5
125000002947 alkylene group Chemical group 0.000 description 5
125000004658 aryl carbonyl amino group Chemical group 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
230000029142 excretion Effects 0.000 description 5
229910052731 fluorine Inorganic materials 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000035780 glucosuria Effects 0.000 description 5
125000001188 haloalkyl group Chemical group 0.000 description 5
125000005842 heteroatom Chemical group 0.000 description 5
230000002218 hypoglycaemic effect Effects 0.000 description 5
239000012535 impurity Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
150000003254 radicals Chemical class 0.000 description 5
150000003573 thiols Chemical class 0.000 description 5
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
KRBNGGIQTIMZEZ-UHFFFAOYSA-N 4-bromo-2-[(4-methoxyphenyl)methyl]-1-methylbenzene Chemical compound C1=CC(OC)=CC=C1CC1=CC(Br)=CC=C1C KRBNGGIQTIMZEZ-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
102000034534 Cotransporters Human genes 0.000 description 4
108020003264 Cotransporters Proteins 0.000 description 4
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
102000042092 Glucose transporter family Human genes 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical class C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
125000005236 alkanoylamino group Chemical group 0.000 description 4
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
125000004104 aryloxy group Chemical group 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
239000012230 colorless oil Substances 0.000 description 4
125000000392 cycloalkenyl group Chemical group 0.000 description 4
239000003480 eluent Substances 0.000 description 4
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
229960004580 glibenclamide Drugs 0.000 description 4
230000006377 glucose transport Effects 0.000 description 4
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
201000001119 neuropathy Diseases 0.000 description 4
230000007823 neuropathy Effects 0.000 description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
208000033808 peripheral neuropathy Diseases 0.000 description 4
150000004756 silanes Chemical class 0.000 description 4
KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 4
229910000080 stannane Inorganic materials 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
GWEKPQSXQGUPRS-UHFFFAOYSA-N (3-bromophenyl)-(4-methoxyphenyl)methanol Chemical compound C1=CC(OC)=CC=C1C(O)C1=CC=CC(Br)=C1 GWEKPQSXQGUPRS-UHFFFAOYSA-N 0.000 description 3
POGKUSUGIRQUAV-UHFFFAOYSA-N (5-bromo-2-methoxyphenyl)-(4-ethylphenyl)methanol Chemical compound C1=CC(CC)=CC=C1C(O)C1=CC(Br)=CC=C1OC POGKUSUGIRQUAV-UHFFFAOYSA-N 0.000 description 3
ZEDYNUOQIHWKIW-UHFFFAOYSA-N (5-bromo-2-methylphenyl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC(Br)=CC=C1C ZEDYNUOQIHWKIW-UHFFFAOYSA-N 0.000 description 3
GAECNRSTNDHUBE-UHFFFAOYSA-N 1-[4-(chloromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(CCl)C=C1 GAECNRSTNDHUBE-UHFFFAOYSA-N 0.000 description 3
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
SEENCYZQHCUTSB-UHFFFAOYSA-N 5-bromo-2-methylbenzoic acid Chemical compound CC1=CC=C(Br)C=C1C(O)=O SEENCYZQHCUTSB-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
206010012655 Diabetic complications Diseases 0.000 description 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
102000023984 PPAR alpha Human genes 0.000 description 3
108010028924 PPAR alpha Proteins 0.000 description 3
102000000536 PPAR gamma Human genes 0.000 description 3
108010016731 PPAR gamma Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 3
108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000002058 anti-hyperglycaemic effect Effects 0.000 description 3
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000001914 filtration Methods 0.000 description 3
125000004446 heteroarylalkyl group Chemical group 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
235000001968 nicotinic acid Nutrition 0.000 description 3
239000011664 nicotinic acid Substances 0.000 description 3
238000010606 normalization Methods 0.000 description 3
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
239000000106 platelet aggregation inhibitor Substances 0.000 description 3
235000013824 polyphenols Nutrition 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000012258 stirred mixture Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 2
LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 2
IMPAHAAQZMNZHW-UHFFFAOYSA-N (3-bromophenyl)-(4-ethylphenyl)methanol Chemical compound C1=CC(CC)=CC=C1C(O)C1=CC=CC(Br)=C1 IMPAHAAQZMNZHW-UHFFFAOYSA-N 0.000 description 2
NIEQZZXEZYUFMQ-UHFFFAOYSA-N (5-bromo-2-chlorophenyl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC(Br)=CC=C1Cl NIEQZZXEZYUFMQ-UHFFFAOYSA-N 0.000 description 2
LEWYCBRUDUVOLG-UHFFFAOYSA-N 1,1,2,2-tetrafluoro-2-(1,1,2,2,3,3,4,4-octafluoro-4-iodobutoxy)ethanesulfonyl fluoride Chemical compound FC(F)(I)C(F)(F)C(F)(F)C(F)(F)OC(F)(F)C(F)(F)S(F)(=O)=O LEWYCBRUDUVOLG-UHFFFAOYSA-N 0.000 description 2
JSRLURSZEMLAFO-UHFFFAOYSA-N 1,3-dibromobenzene Chemical compound BrC1=CC=CC(Br)=C1 JSRLURSZEMLAFO-UHFFFAOYSA-N 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
AKEUNCKRJATALU-UHFFFAOYSA-N 2,6-dihydroxybenzoic acid Chemical compound OC(=O)C1=C(O)C=CC=C1O AKEUNCKRJATALU-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
FGERXQWKKIVFQG-UHFFFAOYSA-N 5-bromo-2-chlorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1Cl FGERXQWKKIVFQG-UHFFFAOYSA-N 0.000 description 2
JOGHNBXDSOKTPG-UHFFFAOYSA-N 5-bromo-2-methylbenzoyl chloride Chemical compound CC1=CC=C(Br)C=C1C(Cl)=O JOGHNBXDSOKTPG-UHFFFAOYSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
229940123413 Angiotensin II antagonist Drugs 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
101710178035 Chorismate synthase 2 Proteins 0.000 description 2
101710152694 Cysteine synthase 2 Proteins 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
ATZKAUGGNMSCCY-VVFNRDJMSA-N [(1r,2r,3r)-2-[(3e)-4,8-dimethylnona-3,7-dienyl]-2-methyl-3-[(1e,5e)-2,6,10-trimethylundeca-1,5,9-trienyl]cyclopropyl]methyl phosphono hydrogen phosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\[C@@H]1[C@@H](COP(O)(=O)OP(O)(O)=O)[C@]1(C)CC\C=C(/C)CCC=C(C)C ATZKAUGGNMSCCY-VVFNRDJMSA-N 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000009471 action Effects 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
125000004419 alkynylene group Chemical group 0.000 description 2
239000002160 alpha blocker Substances 0.000 description 2
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
239000003529 anticholesteremic agent Substances 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
150000004283 biguanides Chemical class 0.000 description 2
229920000080 bile acid sequestrant Polymers 0.000 description 2
229940096699 bile acid sequestrants Drugs 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 2
238000013461 design Methods 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
208000005594 glucose-galactose malabsorption Diseases 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
230000000055 hyoplipidemic effect Effects 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
125000000468 ketone group Chemical group 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
229940057061 mevalonolactone Drugs 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
239000003538 oral antidiabetic agent Substances 0.000 description 2
150000002900 organolithium compounds Chemical class 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
235000015320 potassium carbonate Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
229960003912 probucol Drugs 0.000 description 2
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000030558 renal glucose absorption Effects 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000004001 thioalkyl group Chemical group 0.000 description 2
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
RICKQPKTSOSCOF-HKUYNNGSSA-N (3s)-2-[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1C2=CC=CC=C2C[C@@H](C(O)=O)N1C(=O)[C@@H](N)CC1=CNC2=CC=CC=C12 RICKQPKTSOSCOF-HKUYNNGSSA-N 0.000 description 1
RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 description 1
PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical class O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 description 1
WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
LBMKFQMJURUPKC-UHFFFAOYSA-N 1-(chloromethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CCl)C=C1 LBMKFQMJURUPKC-UHFFFAOYSA-N 0.000 description 1
VWVZFHRDLPHBEG-UHFFFAOYSA-N 1-(chloromethyl)-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(CCl)C=C1 VWVZFHRDLPHBEG-UHFFFAOYSA-N 0.000 description 1
POQMHHDKXWTFHB-UHFFFAOYSA-N 1-[5-[(4,5-diphenyl-1h-imidazol-2-yl)sulfinyl]pentyl]-3,5-dimethylpyrazole Chemical compound N1=C(C)C=C(C)N1CCCCCS(=O)C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 POQMHHDKXWTFHB-UHFFFAOYSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
BSZXAFXFTLXUFV-UHFFFAOYSA-N 1-phenylethylbenzene Chemical compound C=1C=CC=CC=1C(C)C1=CC=CC=C1 BSZXAFXFTLXUFV-UHFFFAOYSA-N 0.000 description 1
229940123153 15 Lipoxygenase inhibitor Drugs 0.000 description 1
BQMPGKPTOHKYHS-UHFFFAOYSA-N 1h-pyrrole-2-carbonitrile Chemical class N#CC1=CC=CN1 BQMPGKPTOHKYHS-UHFFFAOYSA-N 0.000 description 1
PCYWMDGJYQAMCR-UHFFFAOYSA-N 1h-pyrrole-3-carbonitrile Chemical class N#CC=1C=CNC=1 PCYWMDGJYQAMCR-UHFFFAOYSA-N 0.000 description 1
QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical compound CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
125000006040 2-hexenyl group Chemical group 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
NBYATBIMYLFITE-UHFFFAOYSA-N 3-[decyl(dimethyl)silyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide Chemical compound C=1C=CC=CC=1C(NC(=O)CC[Si](C)(C)CCCCCCCCCC)CC1=CC=C(C)C=C1 NBYATBIMYLFITE-UHFFFAOYSA-N 0.000 description 1
SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
125000006041 3-hexenyl group Chemical group 0.000 description 1
RIZIYJOVNPJCDN-UHFFFAOYSA-N 3-hydroxy-4-phosphonobutanoic acid Chemical class OC(=O)CC(O)CP(O)(O)=O RIZIYJOVNPJCDN-UHFFFAOYSA-N 0.000 description 1
RCOVTJVRTZGSBP-UHFFFAOYSA-N 4-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=C(C(Cl)=O)C=C1 RCOVTJVRTZGSBP-UHFFFAOYSA-N 0.000 description 1
FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
MXNQOXJLUJUCGE-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 MXNQOXJLUJUCGE-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
IJIBRSFAXRFPPN-UHFFFAOYSA-N 5-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C=C1C=O IJIBRSFAXRFPPN-UHFFFAOYSA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
229910015845 BBr3 Inorganic materials 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000004072 C09CA03 - Valsartan Substances 0.000 description 1
239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
HPJYKMSFRBJOSW-JHSUYXJUSA-N Damsin Chemical compound C[C@H]1CC[C@H]2C(=C)C(=O)O[C@H]2[C@]2(C)C(=O)CC[C@@H]12 HPJYKMSFRBJOSW-JHSUYXJUSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
206010014418 Electrolyte imbalance Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108010066671 Enalaprilat Proteins 0.000 description 1
108010056764 Eptifibatide Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000716688 Homo sapiens Sodium/glucose cotransporter 1 Proteins 0.000 description 1
101000716682 Homo sapiens Sodium/glucose cotransporter 2 Proteins 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010052341 Impaired insulin secretion Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229940122199 Insulin secretagogue Drugs 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
PMRVFZXOCRHXFE-FMEJWYFOSA-L Kad 1229 Chemical compound [Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 PMRVFZXOCRHXFE-FMEJWYFOSA-L 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241001648341 Orites Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
101150024701 PPH3 gene Proteins 0.000 description 1
101150003085 Pdcl gene Proteins 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
101100095088 Rattus norvegicus Slc5a2 gene Proteins 0.000 description 1
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
CYAYKKUWALRRPA-RGDJUOJXSA-N [(2r,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O CYAYKKUWALRRPA-RGDJUOJXSA-N 0.000 description 1
MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
229960000446 abciximab Drugs 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000012345 acetylating agent Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 1
229950000146 acifran Drugs 0.000 description 1
229960003526 acipimox Drugs 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910001413 alkali metal ion Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
229960001694 anagrelide Drugs 0.000 description 1
OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000005018 aryl alkenyl group Chemical group 0.000 description 1
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
125000001691 aryl alkyl amino group Chemical group 0.000 description 1
125000004659 aryl alkyl thio group Chemical group 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
125000005015 aryl alkynyl group Chemical group 0.000 description 1
125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
125000005135 aryl sulfinyl group Chemical group 0.000 description 1
125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
125000005164 aryl thioalkyl group Chemical group 0.000 description 1
125000005325 aryloxy aryl group Chemical group 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000005518 carboxamido group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
229960004195 carvedilol Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000001906 cholesterol absorption Effects 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
229950003072 clinofibrate Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
229960003009 clopidogrel Drugs 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
150000001942 cyclopropanes Chemical class 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229950006689 darglitazone Drugs 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
229940120124 dichloroacetate Drugs 0.000 description 1
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical class [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960001389 doxazosin Drugs 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
229940125542 dual agonist Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960002680 enalaprilat Drugs 0.000 description 1
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
229950002375 englitazone Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
229960004468 eptifibatide Drugs 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
WCZBUQIZTSIQFE-UHFFFAOYSA-N furan;thiophene Chemical compound C=1C=COC=1.C=1C=CSC=1 WCZBUQIZTSIQFE-UHFFFAOYSA-N 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
229950006480 gemopatrilat Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
230000004190 glucose uptake Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960002048 guanfacine Drugs 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
125000005368 heteroarylthio group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
102000052194 human SLC5A1 Human genes 0.000 description 1
102000052543 human SLC5A2 Human genes 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
230000035879 hyperinsulinaemia Effects 0.000 description 1
230000000871 hypocholesterolemic effect Effects 0.000 description 1
229950010293 imanixil Drugs 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
229960004569 indapamide Drugs 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000006362 insulin response pathway Effects 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229960002198 irbesartan Drugs 0.000 description 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical class O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
229910001416 lithium ion Inorganic materials 0.000 description 1
230000004807 localization Effects 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229950008446 melinamide Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
125000005911 methyl carbonate group Chemical class 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
229950009116 mevastatin Drugs 0.000 description 1
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
229960003365 mitiglinide Drugs 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229960005170 moexipril Drugs 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
230000035772 mutation Effects 0.000 description 1
SYGACMXWLAQEPN-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]ethanamine Chemical compound CCNCC1=CC=C(OC)C=C1 SYGACMXWLAQEPN-UHFFFAOYSA-N 0.000 description 1
BNRAMASAFGTRKZ-UHFFFAOYSA-N n-ethyl-2,6-dihydroxy-n-[(4-methoxyphenyl)methyl]benzamide Chemical compound OC=1C=CC=C(O)C=1C(=O)N(CC)CC1=CC=C(OC)C=C1 BNRAMASAFGTRKZ-UHFFFAOYSA-N 0.000 description 1
ARUNSGOCVDIGTM-UHFFFAOYSA-N n-methyl-n-(propyliminomethylideneamino)methanamine;hydrochloride Chemical compound Cl.CCCN=C=NN(C)C ARUNSGOCVDIGTM-UHFFFAOYSA-N 0.000 description 1
WGESLFUSXZBFQF-UHFFFAOYSA-N n-methyl-n-prop-2-enylprop-2-en-1-amine Chemical class C=CCN(C)CC=C WGESLFUSXZBFQF-UHFFFAOYSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
229950000973 omapatrilat Drugs 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
210000002824 peroxisome Anatomy 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
125000005547 pivalate group Chemical group 0.000 description 1
229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
206010036067 polydipsia Diseases 0.000 description 1
125000006684 polyhaloalkyl group Polymers 0.000 description 1
208000022530 polyphagia Diseases 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000003217 pyrazoles Chemical class 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
229960005187 telmisartan Drugs 0.000 description 1
229960001693 terazosin Drugs 0.000 description 1
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
229960005001 ticlopidine Drugs 0.000 description 1
229960003425 tirofiban Drugs 0.000 description 1
COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
229960002051 trandolapril Drugs 0.000 description 1
230000032258 transport Effects 0.000 description 1
TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000007514 turning Methods 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229960004699 valsartan Drugs 0.000 description 1
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Hematology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

NO20021721A 1999-10-12 2002-04-11 C-aryl-glukosid-SGLT2-inhibitorer, farmasoytiske blandinger og kombinasjoner inneholdende disse, anvendelse av disse for fremstilling av farmasoytisk preparat til behandling samt et mellomprodukt for fremstilling. NO323698B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15877399P	1999-10-12	1999-10-12
US19461500P	2000-04-05	2000-04-05
PCT/US2000/027187 WO2001027128A1 (en)	1999-10-12	2000-10-02	C-aryl glucoside sglt2 inhibitors

Publications (3)

Publication Number	Publication Date
NO20021721D0 NO20021721D0 (no)	2002-04-11
NO20021721L NO20021721L (no)	2002-06-10
NO323698B1 true NO323698B1 (no)	2007-06-25

Family

ID=26855382

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20021721A NO323698B1 (no)	1999-10-12	2002-04-11	C-aryl-glukosid-SGLT2-inhibitorer, farmasoytiske blandinger og kombinasjoner inneholdende disse, anvendelse av disse for fremstilling av farmasoytisk preparat til behandling samt et mellomprodukt for fremstilling.
NO20070149A NO332798B1 (no)	1999-10-12	2007-01-09	Mellomprodukter for syntese av C-aryl-glukosid-SGLT2-inhibitorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20070149A NO332798B1 (no)	1999-10-12	2007-01-09	Mellomprodukter for syntese av C-aryl-glukosid-SGLT2-inhibitorer

Country Status (32)

Country	Link
US (1)	US6414126B1 (pl)
EP (1)	EP1224195B1 (pl)
JP (1)	JP4365554B2 (pl)
KR (1)	KR100728085B1 (pl)
CN (1)	CN1284793C (pl)
AR (1)	AR026024A1 (pl)
AT (1)	ATE295848T1 (pl)
AU (1)	AU781009B2 (pl)
BR (2)	BR0014722A (pl)
CA (1)	CA2388818C (pl)
CO (1)	CO5251414A1 (pl)
CZ (1)	CZ304522B6 (pl)
DE (1)	DE60020259T2 (pl)
EG (1)	EG24515A (pl)
ES (1)	ES2240179T3 (pl)
HK (1)	HK1044541B (pl)
HU (2)	HU229446B1 (pl)
IL (2)	IL148806A0 (pl)
IN (1)	IN2007MU00019A (pl)
MX (1)	MX237254B (pl)
MY (1)	MY125405A (pl)
NO (2)	NO323698B1 (pl)
NZ (1)	NZ518029A (pl)
PE (1)	PE20011000A1 (pl)
PH (1)	PH12000002657B1 (pl)
PL (1)	PL204358B1 (pl)
PT (1)	PT1224195E (pl)
RU (1)	RU2262507C2 (pl)
TR (1)	TR200200986T2 (pl)
TW (1)	TWI254714B (pl)
UY (1)	UY26391A1 (pl)
WO (1)	WO2001027128A1 (pl)

Families Citing this family (323)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh) *	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PT1616561E (pt) *	1999-12-28	2008-07-09	Ajinomoto Kk	Preparação antidiabética para administração oral
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
EP1274720A4 (en)	2000-04-12	2004-08-18	Human Genome Sciences Inc	FUSION PROTEINS CONTAINING ALBUMIN
FR2809310B1 (fr) *	2000-05-26	2004-02-13	Centre Nat Rech Scient	Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
NZ537490A (en) *	2000-10-30	2006-11-30	Ortho Mcneil Pharm Inc	Treatment of diabetes and syndrome X using a sulfamate derivate such as topiramate and metformin
JP2004525109A (ja) *	2001-02-15	2004-08-19	キング・ファーマシューティカルズ・インコーポレイティッド	安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030224047A1 (en) *	2001-02-15	2003-12-04	Franz G. Andrew	Levothyroxine compositions and methods
US20030032675A1 (en) *	2001-02-15	2003-02-13	Franz G. Andrew	Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en)	2001-02-15	2003-04-29	Jones Pharma, Inc.	Levothyroxine compositions and methods
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
JP4590159B2 (ja)	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ES2258141T3 (es) *	2001-04-11	2006-08-16	Bristol-Myers Squibb Company	Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
JPWO2003011880A1 (ja) *	2001-07-31	2004-11-18	キッセイ薬品工業株式会社	グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US20030180353A1 (en) *	2001-08-10	2003-09-25	Franz G. Andrew	Stabilized pharmaceutical compositions
US20030198667A1 (en) *	2001-08-10	2003-10-23	Franz Andrew G.	Methods of producing dispersible pharmaceutical compositions
US20030190349A1 (en) *	2001-08-10	2003-10-09	Franz G. Andrew	Methods of stabilizing pharmaceutical compositions
US20030195253A1 (en) *	2001-08-14	2003-10-16	Franz G. Andrew	Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030203967A1 (en) *	2001-08-14	2003-10-30	Franz G. Andrew	Levothyroxine compositions having unique Tmax properties
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
US20030199586A1 (en) *	2001-08-14	2003-10-23	Franz G. Andrew	Unique levothyroxine aqueous materials
US20030198672A1 (en) *	2001-08-14	2003-10-23	Franz G. Andrew	Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199587A1 (en) *	2001-08-14	2003-10-23	Franz G. Andrew	Levothyroxine compositions having unique Cmax properties
US20040043066A1 (en) *	2001-10-29	2004-03-04	Franz G. Andrew	Levothyroxine compositions having unique triiodothyronine Tmax properties
US6806381B2 (en) *	2001-11-02	2004-10-19	Bristol-Myers Squibb Company	Process for the preparation of aniline-derived thyroid receptor ligands
WO2003043624A1 (en) *	2001-11-16	2003-05-30	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
AU2002351752A1 (en) *	2001-12-29	2003-07-30	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20060052457A1 (en) *	2002-03-11	2006-03-09	Peter Zahradka	Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20050215489A1 (en) *	2002-03-14	2005-09-29	Bayer Pharmaceuticals Corporation	Methods of treating diabetes using pde 11a inhibitors
US7956041B2 (en)	2002-04-26	2011-06-07	Ajinomoto Co., Inc.	Prophylactic and therapeutic agent of diabetes mellitus
EP1500403A4 (en) *	2002-04-26	2008-09-17	Ajinomoto Kk	MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
CA2500873C (en) *	2002-10-04	2012-01-17	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) *	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2003299966A1 (en)	2003-01-03	2004-08-10	Bristol-Myers Squibb Company	Methods of producing c-aryl glucoside sglt2 inhibitors
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
EP1457206A1 (en) *	2003-03-13	2004-09-15	Fournier Laboratories Ireland Limited	Combined use of a fibrate and orlistat for the treatment of obesity
CN1802366B (zh) *	2003-03-14	2010-12-22	安斯泰来制药有限公司	C-糖苷衍生物及其盐
JP2004300102A (ja)	2003-03-31	2004-10-28	Kissei Pharmaceut Co Ltd	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2004233693B2 (en) *	2003-04-28	2007-07-19	Funahashi, Toru	Adiponectin production enhancer
US7772272B2 (en) *	2003-04-28	2010-08-10	Daiichi Sankyo Company, Limited	Method for enhancing glucose uptake into warm-blooded animal adipocytes
US7459474B2 (en)	2003-06-11	2008-12-02	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
UA86042C2 (en)	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
RS20060320A (sr) *	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Supstituisani indazol-o-glukozidi
TW200524951A (en)	2003-08-01	2005-08-01	Janssen Pharmaceutica Nv	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
AU2004261660A1 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted fused heterocyclic C-glycosides
MXPA06001274A (es)	2003-08-01	2006-04-11	Tanabe Seiyaku Co	Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
EP1680131A4 (en)	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED INDOLE-O-GLUCOSIDES
US7375090B2 (en)	2003-08-26	2008-05-20	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050054731A1 (en) *	2003-09-08	2005-03-10	Franco Folli	Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) *	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
WO2005038013A1 (en) *	2003-10-07	2005-04-28	Isis Pharmaceuticals, Inc.	Artisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) *	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
EP1689757B1 (en)	2003-11-12	2014-08-27	Phenomix Corporation	Heterocyclic boronic acid compounds
US7420059B2 (en) *	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
EP1581246B1 (en) *	2003-12-17	2013-01-16	Amylin Pharmaceuticals, LLC	Compositions for the treatment and prevention of nephropathy
JP2006514649A (ja) *	2003-12-17	2006-05-11	アミリン・ファーマシューティカルズ，インコーポレイテッド	腎症の治療および予防のための組成物
US7371732B2 (en) *	2003-12-22	2008-05-13	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
WO2005085237A1 (ja) *	2004-03-04	2005-09-15	Kissei Pharmaceutical Co., Ltd.	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
RU2387663C2 (ru) *	2004-03-04	2010-04-27	Киссеи Фармасьютикал Ко., Лтд.	Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
EP2360165A3 (de)	2004-03-16	2012-01-04	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2560005A1 (en) *	2004-03-31	2005-10-13	Kissei Pharmaceutical Co., Ltd.	Phenol derivative, medicinal composition containing the same, and medicinal use thereof
TW200602335A (en) *	2004-03-31	2006-01-16	Kissei Pharmaceutical	Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
JPWO2005095372A1 (ja) *	2004-03-31	2008-02-21	キッセイ薬品工業株式会社	ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
DE102004028241B4 (de) *	2004-06-11	2007-09-13	Sanofi-Aventis Deutschland Gmbh	Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US20070293690A1 (en) *	2004-07-08	2007-12-20	Hiroshi Tomiyama	Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
EP1782828B1 (en) *	2004-07-21	2016-06-29	Kissei Pharmaceutical Co., Ltd.	Progression inhibitor for disease attributed to abnormal accumulation of liver fat
TW200606129A (en)	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) *	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) *	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP5046370B2 (ja) *	2004-09-29	2012-10-10	キッセイ薬品工業株式会社	１−（β−Ｄ−グリコピラノシル）−３−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
DE102004048388A1 (de) *	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006064033A2 (en)	2004-12-16	2006-06-22	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
ZA200706022B (en) *	2005-01-28	2008-11-26	Chugai Pharmaceutical Co Ltd	Spiroketal derivatives and use thereof as diabetic medicine
MY147375A (en)	2005-01-31	2012-11-30	Mitsubishi Tanabe Pharma Corp	Indole derivatives
JP4496174B2 (ja) *	2005-01-31	2010-07-07	田辺三菱製薬株式会社	医薬組成物
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
EP1846410B1 (en) *	2005-02-10	2009-01-21	Bristol-Myers Squibb Company	Dihydroquinazolinones as 5ht modulators
WO2006089872A1 (en) *	2005-02-23	2006-08-31	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
WO2006099245A1 (en) *	2005-03-11	2006-09-21	Elixir Pharmaceuticals, Inc.	Sirt inhibitors that bind to nad
EP2527337A1 (en)	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
ATE453656T1 (de)	2005-04-15	2010-01-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en)	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk)	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TW200726746A (en) *	2005-05-06	2007-07-16	Microbia Inc	Processes for production of 4-biphenylylazetidin-2-ones
US7772191B2 (en) *	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) *	2005-06-29	2007-01-04	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) *	2005-07-07	2007-07-16	Astellas Pharma Inc	A crystalline choline salt of an azulene derivative
WO2007011524A1 (en) *	2005-07-14	2007-01-25	Franco Folli	Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
ES2346347T3 (es) *	2005-07-27	2010-10-14	Boehringer Ingelheim International Gmbh	Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
JP2009502959A (ja) *	2005-07-28	2009-01-29	ブリストル−マイヤーズスクイブカンパニー	セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) *	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
ATE484499T1 (de) *	2005-08-30	2010-10-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
CN101238112A (zh)	2005-09-08	2008-08-06	贝林格尔·英格海姆国际有限公司	1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途
AR056195A1 (es)	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AU2007216452A1 (en)	2006-02-15	2007-08-23	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20070238770A1 (en) *	2006-04-05	2007-10-11	Bristol-Myers Squibb Company	Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
TWI370818B (en) *	2006-04-05	2012-08-21	Astellas Pharma Inc	Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
TW200812995A (en)	2006-05-19	2008-03-16	Taisho Pharmaceutical Co Ltd	C-phenyl glycitol compound
US7803778B2 (en) *	2006-05-23	2010-09-28	Theracos, Inc.	Glucose transport inhibitors and methods of use
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2655937A1 (en) *	2006-06-29	2008-01-03	Taisho Pharmaceutical Co., Ltd.	C-phenyl 1-thioglucitol compound
US7910747B2 (en)	2006-07-06	2011-03-22	Bristol-Myers Squibb Company	Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008005910A2 (en)	2006-07-06	2008-01-10	Bristol-Myers Squibb Company	Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7795291B2 (en)	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI432446B (zh)	2006-07-27	2014-04-01	Chugai Pharmaceutical Co Ltd	稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh)	2006-07-27	2013-08-01	Chugai Pharmaceutical Co Ltd	To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
CA2656847A1 (en) *	2006-08-15	2008-02-21	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7858587B2 (en) *	2006-09-21	2010-12-28	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
CN101522699A (zh)	2006-10-13	2009-09-02	中外制药株式会社	硫葡萄糖螺缩酮衍生物、及其作为糖尿病治疗药的应用
EP2086991A1 (en)	2006-10-27	2009-08-12	Boehringer Ingelheim International GmbH	CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5298025B2 (ja) *	2006-12-04	2013-09-25	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体
CN101657471B (zh)	2006-12-06	2013-07-03	史密丝克莱恩比彻姆公司	二环化合物及其作为抗糖尿病药的用途
MX2009006444A (es)	2006-12-21	2009-06-26	Astellas Pharma Inc	Metodo para producir derivado de c-glucosido e intermediario sintetico del mismo.
US7795228B2 (en) *	2006-12-28	2010-09-14	Theracos, Inc.	Spiroheterocyclic glycosides and methods of use
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
JP2010519273A (ja) *	2007-02-21	2010-06-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
US7846945B2 (en) *	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TW200904454A (en)	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es)	2007-03-22	2009-07-01	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN104803957A (zh) *	2007-04-02	2015-07-29	泰拉科斯有限公司	苄基化糖苷衍生物及其用法
WO2008130951A1 (en)	2007-04-17	2008-10-30	Bristol-Myers Squibb Company	Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
JP2010528023A (ja) *	2007-05-18	2010-08-19	ブリストル−マイヤーズスクイブカンパニー	Ｓｇｌｔ２阻害剤の結晶構造およびその製造方法
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es)	2007-06-04	2010-02-15	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
DE602008006081D1 (de)	2007-07-05	2011-05-19	Centre Nat Rech Scient	Neue phosphorhaltige heterocyclische verbindungen, zuckeranaloga und zusammensetzungen mit antikrebswirkung, die diese enthalten
CN101343296B (zh) *	2007-07-10	2013-04-10	莱西肯医药有限公司	钠-葡萄糖协同转运蛋白2的抑制剂及其用法
ES2375800T3 (es) *	2007-07-26	2012-03-06	Lexicon Pharmaceuticals, Inc.	Métodos y compuestos útiles para la preparación de inhibidores de cotransportador 2 de sódio-glucosa.
CN101808995A (zh) *	2007-07-27	2010-08-18	百时美施贵宝公司	新颖的葡糖激酶激活剂及其使用方法
PE20090938A1 (es)	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2009026537A1 (en)	2007-08-23	2009-02-26	Theracos, Inc.	Benzylbenzene derivatives and methods of use
CN101801371B (zh)	2007-09-10	2012-11-28	詹森药业有限公司	可用作sglt抑制剂的化合物的制备方法
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) *	2008-02-04	2012-06-27	白鹭医药技术（上海）有限公司	C-芳基葡萄糖苷sglt2抑制剂
US8450286B2 (en)	2008-03-18	2013-05-28	Bristol-Myers Squibb Company	Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof
FR2929615B1 (fr) *	2008-04-02	2010-12-17	Tfchem	Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
BRPI0913129A2 (pt)	2008-05-22	2016-01-05	Bristol Myers Squibb Co	método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009243A1 (en)	2008-07-15	2010-01-21	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PT2324002T (pt)	2008-08-22	2016-11-09	Theracos Sub Llc	Processos para a preparação de inibidores de sglt2
MX2011002166A (es) *	2008-08-28	2011-04-07	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
RU2411936C2 (ru) *	2009-01-11	2011-02-20	Институт физиологии Коми научного центра Уральского отделения Российской академии наук. Государственное учреждение	Применение 2-морфолино-5-фенил-6н-1,3,4-тиадизин, гидробромида в качестве средства, обладающего гиполипидемическим и гипергликемическим эффектом
MY161472A (en)	2009-02-13	2017-04-14	Boehringer Ingelheim Int	Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
PL2395983T3 (pl)	2009-02-13	2020-09-07	Boehringer Ingelheim International Gmbh	Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
MX345494B (es) *	2009-02-13	2017-02-02	Boehringer Ingelheim Int Gmbh *	Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
WO2010104830A1 (en)	2009-03-09	2010-09-16	Bristol-Myers Squibb Company	Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8278316B2 (en)	2009-03-09	2012-10-02	Bristol-Myers Squibb Company	Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2435033A1 (en) *	2009-05-27	2012-04-04	Bristol-Myers Squibb Company	Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
KR101532412B1 (ko)	2009-07-10	2015-06-29	얀센 파마슈티카 엔.브이.	1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
HUE029381T2 (en)	2009-09-30	2017-02-28	Boehringer Ingelheim Int	Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
BR112012007085B8 (pt)	2009-09-30	2021-05-25	Boehringer Ingelheim Int	processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
US10610489B2 (en) *	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
SG10201500258WA (en)	2009-10-14	2015-03-30	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
US8163704B2 (en)	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
KR20120087950A (ko)	2009-10-20	2012-08-07	노파르티스 아게	글리코시드 유도체 및 그의 용도
NZ599945A (en)	2009-11-02	2014-05-30	Pfizer	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
CN104825417A (zh)	2009-11-13	2015-08-12	阿斯利康(瑞典)有限公司	立即释放片剂
WO2011070592A2 (en) *	2009-12-09	2011-06-16	Panacea Biotec Ltd.	Novel sugar derivatives
TWI562775B (en)	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20140088027A1 (en)	2010-03-30	2014-03-27	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2011130459A1 (en)	2010-04-14	2011-10-20	Bristol-Myers Squibb Company	Novel glucokinase activators and methods of using same
LT2568988T (lt)	2010-05-11	2016-09-12	Janssen Pharmaceutica, N.V.	Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
WO2011153712A1 (en) *	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
WO2012025857A1 (en)	2010-08-23	2012-03-01	Hetero Research Foundation	Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
AU2011295837B2 (en)	2010-09-03	2015-06-18	Astrazeneca Uk Limited	Drug formulations using water soluble antioxidants
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en)	2010-09-29	2012-04-05	Celon Pharma Sp. Z O.O.	Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh)	2010-10-27	2012-05-16	上海艾力斯医药科技有限公司	C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
IL295438B2 (en)	2011-01-05	2026-05-01	Lexicon Pharmaceuticals Inc	Compositions containing and methods for using inhibitors of sodium-glucose cotransporters 1 and 2
EP2670397B1 (en)	2011-02-01	2020-05-13	Bristol-Myers Squibb Company	Pharmaceutical formulations including an amine compound
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
WO2012109996A1 (zh)	2011-02-18	2012-08-23	上海璎黎科技有限公司	一种芳基糖苷类化合物及其制备方法和应用
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102675378A (zh) *	2011-03-09	2012-09-19	天津药物研究院	一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
WO2012125622A1 (en)	2011-03-14	2012-09-20	Bristol-Myers Squibb Company	Substituted adipic acid amides and uses thereof
AU2012241897C1 (en)	2011-04-13	2017-05-11	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of SGLT2
CN103619862A (zh)	2011-04-14	2014-03-05	诺瓦提斯公司	糖苷衍生物及其用途
US8614195B2 (en)	2011-04-14	2013-12-24	Novartis Ag	Glycoside derivatives and uses thereof
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
JP5876570B2 (ja) *	2011-06-01	2016-03-02	グリーン・クロス・コーポレイションＧｒｅｅｎＣｒｏｓｓＣｏｒｐ．	Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体
EA201301354A1 (ru)	2011-06-03	2014-05-30	Бёрингер Ингельхайм Интернациональ Гмбх	Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
WO2012172566A2 (en) *	2011-06-13	2012-12-20	Panacea Biotec Ltd.	Novel sglt inhibitors
CN102827122B (zh) *	2011-06-17	2015-01-14	山东轩竹医药科技有限公司	糖苷衍生物
WO2013000275A1 (zh) *	2011-06-25	2013-01-03	山东轩竹医药科技有限公司	C-糖苷衍生物
US20130035298A1 (en)	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US8710049B2 (en)	2011-07-18	2014-04-29	Bristol-Myers Squibb Company	Diaminocyclohexane compounds and uses thereof
US8815909B2 (en)	2011-07-18	2014-08-26	Bristol-Myers Squibb Company	Diaminocyclohexane compounds and uses thereof
EP2755722B1 (en) *	2011-09-13	2017-05-24	Panacea Biotec Ltd.	Novel sglt inhibitors
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
WO2013152476A1 (en)	2012-04-10	2013-10-17	Theracos, Inc.	Process for the preparation of benzylbenzene sglt2 inhibitors
CN103450214B (zh) *	2012-05-29	2016-04-06	广东东阳光药业有限公司	吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
JP6198013B2 (ja) *	2012-08-30	2017-09-20	大正製薬株式会社	Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ
EP2892897A1 (en)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
CN103910769B (zh)	2012-12-31	2018-10-02	上海璎黎药业有限公司	葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de)	2013-03-04	2016-05-18	BioActive Food GmbH	Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
PT3466431T (pt)	2013-03-14	2024-01-26	Msd Int Gmbh	Formas cristalinas e métodos para preparação de inibidores de sglt2
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN104059042B (zh) *	2013-03-22	2017-02-08	正大天晴药业集团股份有限公司	C-三芳基葡萄糖苷类sglt-2抑制剂
EP4245765A3 (en)	2013-04-04	2024-03-20	Boehringer Ingelheim Vetmedica GmbH	Treatment of metabolic disorders in equine animals
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr)	2013-04-05	2019-03-08	Boehringer Ingelheim International Gmbh	Terapeutske uporabe empagliflozina
KR102309654B1 (ko)	2013-04-18	2021-10-08	베링거 인겔하임 인터내셔날 게엠베하	약제학적 조성물, 치료 방법 및 이의 용도
EP2991999B1 (en)	2013-04-29	2019-05-08	Mapi Pharma Limited	Dapagliflozin lactose co-crystal
EA201592263A1 (ru)	2013-06-05	2016-05-31	Синерджи Фармасьютикалз, Инк.	Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
CN105518014B (zh) *	2013-09-09	2018-03-23	上海研健新药研发有限公司	C‑芳基葡糖苷衍生物、其制备方法及其在医药上的应用
US9394329B2 (en)	2013-09-27	2016-07-19	Sunshine Lake Pharma Co., Ltd.	Glucopyranosyl derivatives and their uses in medicine
CN105611920B (zh)	2013-10-12	2021-07-16	泰拉科斯萨普有限责任公司	羟基-二苯甲烷衍生物的制备
ES2969764T3 (es)	2013-12-17	2024-05-22	Boehringer Ingelheim Vetmedica Gmbh	Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
WO2015101916A1 (en)	2013-12-30	2015-07-09	Mylan Laboratories Ltd.	Process for the preparation of empagliflozin
US9315438B2 (en)	2014-01-03	2016-04-19	Xuanzhu Pharma Co., Ltd	Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
EP2891654B1 (en)	2014-01-03	2016-06-22	Xuanzhu Pharma Co., Ltd.	Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
CN115282284A (zh) *	2014-01-23	2022-11-04	勃林格殷格翰动物保健有限公司	犬科动物中代谢紊乱的治疗
IN2014CH01141A (pl) *	2014-03-06	2015-09-11	Msn Lab Private Ltd
ES2811261T3 (es)	2014-04-01	2021-03-11	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de trastornos metabólicos en animales equinos
CN105001213B (zh) *	2014-04-14	2020-08-28	上海迪诺医药科技有限公司	C-芳基糖苷衍生物、其药物组合物、制备方法及应用
TW201623321A (zh)	2014-05-13	2016-07-01	韓美藥品股份有限公司	雙環衍生物及包含其之藥學組成物
EP2944311A1 (de)	2014-05-16	2015-11-18	BioActive Food GmbH	Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN105085494B (zh) *	2014-05-22	2019-07-02	中国医学科学院药物研究所	钠糖共转运体2抑制剂、其制法和其药物组合物与用途
JP2017528499A (ja)	2014-09-25	2017-09-28	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
HUE068152T2 (hu)	2014-09-25	2024-12-28	Boehringer Ingelheim Vetmedica Gmbh	SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
CN104327027B (zh) *	2014-10-14	2017-04-05	中国药科大学	一类新型c‑芳基葡萄糖苷sglt2抑制剂
EP3256482B1 (en) *	2015-02-09	2019-11-27	Indoco Remedies Limited	Process for the preparation of sglt inhibitor compounds
HK1249847A1 (zh)	2015-03-09	2018-11-16	Intekrin Therapeutics, Inc.	用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2016161995A1 (en)	2015-04-08	2016-10-13	Zentiva, K.S.	Solid forms of amorphous dapagliflozin
CN106317068A (zh) *	2015-06-23	2017-01-11	中国科学院上海药物研究所	一种c,o-螺环芳基糖苷类化合物及其制备和应用
MX389367B (es)	2015-08-27	2025-03-20	Boehringer Ingelheim Vetmedica Gmbh	Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EP3362055B1 (en)	2015-10-15	2023-01-18	Boehringer Ingelheim International GmbH	Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
WO2017099496A1 (ko)	2015-12-11	2017-06-15	동아에스티 주식회사	다파글리플로진의 신규 용매화물 및 이의 제조방법
CN106892929B (zh) *	2015-12-17	2020-01-14	上海艾力斯医药科技有限公司	螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) *	2015-12-28	2016-06-22	南昌大学	一种抗糖尿病化合物及其制备方法和用途
UA122083C2 (uk) *	2016-01-04	2020-09-10	Че Іль Фармасьютікал Ко., Лтд.	C-глікозидні похідні, які містять конденсоване фенільне кільце, або їхні фармацевтично прийнятні солі, спосіб одержання таких і фармацевтична композиція, що містить такі
WO2017141202A1 (en)	2016-02-17	2017-08-24	Lupin Limited	Complex of sglt2 inhibitor and process for preparation thereof
US9834533B2 (en) *	2016-02-19	2017-12-05	Scinopharm Taiwan, Ltd.	Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017221211A1 (en) *	2016-06-24	2017-12-28	Biocon Limited	Process for the preparation of dapagliflozin and its solvate thereof
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
EA201990951A1 (ru)	2016-10-19	2019-11-29		Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CA3039745A1 (en)	2016-11-10	2018-05-17	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
WO2018167589A1 (en)	2017-03-16	2018-09-20	Inventia Healthcare Private Limited	Pharmaceutical composition comprising dapagliflozin
KR20200036808A (ko)	2017-04-03	2020-04-07	코히러스 바이오사이언시스, 인크.	진행성 핵상 마비 치료를 위한 PPARγ 작용제
KR101943382B1 (ko)	2017-09-19	2019-01-29	오토텔릭바이오 주식회사	Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CN111989103A (zh)	2018-04-17	2020-11-24	勃林格殷格翰国际有限公司	药物组合物、其治疗方法和用途
KR102204439B1 (ko)	2018-05-14	2021-01-18	에이치케이이노엔 주식회사	Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
KR20200022257A (ko) *	2018-08-22	2020-03-03	동아에스티 주식회사	Sglt-2 억제제인 다파글리플로진 전구체의 제조방법
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
WO2020089025A1 (en)	2018-10-29	2020-05-07	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
SG11202102440SA (en)	2018-10-29	2021-04-29	Boehringer Ingelheim Int	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020151621A1 (zh) *	2019-01-24	2020-07-30	北京盈科瑞创新药物研究有限公司	化合物、其制备方法及医药用途
CN111471031B (zh) *	2019-01-24	2023-05-16	北京盈科瑞创新药物研究有限公司	一种糖苷类衍生物及其制备方法和应用
CN111471032B (zh) *	2019-01-24	2023-08-01	北京盈科瑞创新药物研究有限公司	一种糖苷类衍生物的合成方法及其中间体和应用
CN111471040B (zh) *	2019-01-24	2023-06-02	北京盈科瑞创新药物研究有限公司	一种糖苷类衍生物的合成方法及其中间体和应用
CN111840271B (zh) *	2019-04-25	2024-05-14	北京盈科瑞创新药物研究有限公司	一种糖苷类衍生物新用途
JOP20200098A1 (ar)	2019-08-30	2021-02-28	Astrazeneca Ab	طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
CN114727624A (zh)	2019-11-28	2022-07-08	勃林格殷格翰动物保健有限公司	Sglt-2抑制剂在非人哺乳动物的停奶中的用途
PE20231066A1 (es)	2020-02-07	2023-07-17	Gasherbrum Bio Inc	Agonistas heterociclicos de glp-1
KR20220143732A (ko)	2020-02-17	2022-10-25	베링거잉겔하임베트메디카게엠베하	고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
JP2021127332A (ja) *	2020-02-17	2021-09-02	株式会社トクヤマ	５−ブロモ−２−アルキル安息香酸の製造方法
WO2021176096A1 (en)	2020-03-05	2021-09-10	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising sglt2 inhibitor
CN115209894B (zh)	2020-03-06	2025-05-02	弗特克斯药品有限公司	治疗apol-1依赖性局灶节段性肾小球硬化的方法
WO2021214023A1 (en)	2020-04-22	2021-10-28	Bayer Aktiengesellschaft	Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP4143183B1 (en)	2020-04-29	2025-10-22	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
US20230165856A1 (en)	2020-04-29	2023-06-01	Astrazeneca Ab	Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
CN115867538A (zh)	2020-06-05	2023-03-28	新梅斯托克公司	高纯的无定形达格列净的制备
AU2021202643B2 (en)	2020-07-27	2023-02-02	Astrazeneca Ab	Methods of treating chronic kidney disease with dapagliflozin
PT4188389T (pt)	2020-07-27	2025-10-07	Astrazeneca Ab	Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
WO2022028572A1 (en)	2020-08-06	2022-02-10	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
WO2022051316A1 (en)	2020-09-03	2022-03-10	Coherus Biosciences, Inc.	Fixed dose combinations of chs-131 and a sglt-2 inhibitor
EP4249479A4 (en) *	2020-11-19	2024-12-18	Beijing Increase Innovative Drug Co., Ltd.	GLUCOSIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION
KR20220091233A (ko)	2020-12-23	2022-06-30	(주)국전약품	다파글리플로진 전구약물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2022208172A1 (en)	2021-04-01	2022-10-06	Astrazeneca Uk Limited	Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
MX2024001184A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
MX2024001185A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades renales en mamiferos no humanos.
EP4376819A1 (en)	2021-07-28	2024-06-05	Boehringer Ingelheim Vetmedica GmbH	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN118510504A (zh)	2022-01-26	2024-08-16	阿斯利康(瑞典)有限公司	用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
JP2025509281A (ja)	2022-03-09	2025-04-11	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
EP4496797A1 (en)	2022-03-21	2025-01-29	Gasherbrum Bio, Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4508047A1 (en)	2022-04-14	2025-02-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
EP4531810A1 (en)	2022-05-25	2025-04-09	Boehringer Ingelheim Vetmedica GmbH	Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024033288A1 (en) *	2022-08-12	2024-02-15	Société des Produits Nestlé S.A.	Salicin derivatives as inhibitors of sglt2
US20240307628A1 (en)	2023-03-06	2024-09-19	Boehringer Ingelheim Vetmedica Gmbh	Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
KR20260019532A (ko)	2023-05-24	2026-02-10	베링거잉겔하임베트메디카게엠베하	하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
WO2024240632A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2025125513A1 (en)	2023-12-15	2025-06-19	AstraZeneca Ireland Limited	Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
WO2025224069A1 (en)	2024-04-23	2025-10-30	Bayer Aktiengesellschaft	Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5444050A (en)	1994-04-29	1995-08-22	Texas Biotechnology Corporation	Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
JP2814950B2 (ja)	1994-05-11	1998-10-27	田辺製薬株式会社	血糖降下剤
US5830873A (en)	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
CN1149082C (zh)	1995-06-29	2004-05-12	得克萨斯生物技术公司	二价和三价小分子选择蛋白抑制剂
JP3006513B2 (ja)	1995-11-07	2000-02-07	田辺製薬株式会社	医薬組成物
JP3059088B2 (ja)	1995-11-07	2000-07-04	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
JP3065235B2 (ja)	1995-11-07	2000-07-17	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
JP3034192B2 (ja)	1995-11-07	2000-04-17	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
TW406086B (en)	1996-12-26	2000-09-21	Tanabe Seiyaku Co	Propiophenone derivatives and process for preparing the same
AU6024998A (en) *	1997-01-15	1998-08-07	Glycomed Incorporated	Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja)	1997-03-03	1998-09-14	Dainippon Ink & Chem Inc	７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
US6486299B1 (en) *	1998-09-28	2002-11-26	Curagen Corporation	Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en)	1998-09-30	2000-05-30	Eli Lilly And Company	Spirocyclic C-glycosides
UA71994C2 (en) *	1999-08-31	2005-01-17	Kissei Pharmaceutical	Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof

2000
- 2000-09-27 PH PH12000002657A patent/PH12000002657B1/en unknown
- 2000-10-02 HU HU0300393A patent/HU229446B1/hu unknown
- 2000-10-02 DE DE60020259T patent/DE60020259T2/de not_active Expired - Lifetime
- 2000-10-02 NZ NZ518029A patent/NZ518029A/en not_active IP Right Cessation
- 2000-10-02 IL IL14880600A patent/IL148806A0/xx unknown
- 2000-10-02 AT AT00968595T patent/ATE295848T1/de active
- 2000-10-02 CA CA2388818A patent/CA2388818C/en not_active Expired - Lifetime
- 2000-10-02 CN CNB008167419A patent/CN1284793C/zh not_active Expired - Lifetime
- 2000-10-02 BR BR0014722-2A patent/BR0014722A/pt not_active IP Right Cessation
- 2000-10-02 PT PT00968595T patent/PT1224195E/pt unknown
- 2000-10-02 RU RU2002109477/04A patent/RU2262507C2/ru active IP Right Revival
- 2000-10-02 WO PCT/US2000/027187 patent/WO2001027128A1/en not_active Ceased
- 2000-10-02 EP EP00968595A patent/EP1224195B1/en not_active Expired - Lifetime
- 2000-10-02 ES ES00968595T patent/ES2240179T3/es not_active Expired - Lifetime
- 2000-10-02 MX MXPA02003625 patent/MX237254B/es active IP Right Grant
- 2000-10-02 KR KR20027004660A patent/KR100728085B1/ko not_active Expired - Lifetime
- 2000-10-02 CZ CZ2002-1285A patent/CZ304522B6/cs not_active IP Right Cessation
- 2000-10-02 HU HU1200688A patent/HU230727B1/hu unknown
- 2000-10-02 TR TR2002/00986T patent/TR200200986T2/xx unknown
- 2000-10-02 PL PL355018A patent/PL204358B1/pl unknown
- 2000-10-02 HK HK02106026.3A patent/HK1044541B/en unknown
- 2000-10-02 BR BRPI0014722A patent/BRPI0014722B8/pt unknown
- 2000-10-02 AU AU78483/00A patent/AU781009B2/en not_active Expired
- 2000-10-02 JP JP2001530346A patent/JP4365554B2/ja not_active Expired - Lifetime
- 2000-10-04 US US09/679,027 patent/US6414126B1/en not_active Expired - Lifetime
- 2000-10-06 TW TW089120955A patent/TWI254714B/zh not_active IP Right Cessation
- 2000-10-09 EG EG20001279A patent/EG24515A/xx active
- 2000-10-10 CO CO00077048A patent/CO5251414A1/es not_active Application Discontinuation
- 2000-10-10 PE PE2000001082A patent/PE20011000A1/es not_active IP Right Cessation
- 2000-10-11 UY UY26391A patent/UY26391A1/es not_active IP Right Cessation
- 2000-10-11 MY MYPI20004759A patent/MY125405A/en unknown
- 2000-10-12 AR ARP000105373A patent/AR026024A1/es active IP Right Grant
2002
- 2002-03-21 IL IL148806A patent/IL148806A/en active IP Right Grant
- 2002-04-11 NO NO20021721A patent/NO323698B1/no not_active IP Right Cessation
2007
- 2007-01-04 IN IN19MU2007 patent/IN2007MU00019A/en unknown
- 2007-01-09 NO NO20070149A patent/NO332798B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE60020259T2 (de)	2006-01-19
PE20011000A1 (es)	2001-11-25
CA2388818C (en)	2012-07-03
NZ518029A (en)	2004-08-27
HU230727B1 (hu)	2017-12-28
MY125405A (en)	2006-07-31
PH12000002657B1 (en)	2006-02-21
HK1044541B (en)	2005-11-11
EP1224195A1 (en)	2002-07-24
HUP0300393A2 (hu)	2003-06-28
PL204358B1 (pl)	2010-01-29
US6414126B1 (en)	2002-07-02
DE60020259D1 (de)	2005-06-23
RU2002109477A (ru)	2004-01-20
CA2388818A1 (en)	2001-04-19
IN2007MU00019A (pl)	2007-08-03
ES2240179T3 (es)	2005-10-16
NO20070149L (no)	2002-06-10
IL148806A0 (en)	2002-09-12
UY26391A1 (es)	2001-05-31
KR20020063876A (ko)	2002-08-05
CO5251414A1 (es)	2003-02-28
KR100728085B1 (ko)	2007-06-14
WO2001027128A1 (en)	2001-04-19
NO20021721L (no)	2002-06-10
CZ20021285A3 (cs)	2003-02-12
AR026024A1 (es)	2002-12-26
AU781009B2 (en)	2005-04-28
PL355018A1 (pl)	2004-03-22
HUP0300393A3 (en)	2003-09-29
CZ304522B6 (cs)	2014-06-18
EP1224195B1 (en)	2005-05-18
ATE295848T1 (de)	2005-06-15
AU7848300A (en)	2001-04-23
NO332798B1 (no)	2013-01-14
CN1284793C (zh)	2006-11-15
HU229446B1 (en)	2013-12-30
TWI254714B (en)	2006-05-11
RU2262507C2 (ru)	2005-10-20
HK1044541A1 (en)	2002-10-25
BRPI0014722B8 (pt)	2021-05-25
MXPA02003625A (es)	2002-10-23
BR0014722A (pt)	2003-02-25
TR200200986T2 (tr)	2002-07-22
JP4365554B2 (ja)	2009-11-18
MX237254B (es)	2006-05-26
EG24515A (en)	2009-08-19
NO20021721D0 (no)	2002-04-11
JP2003511458A (ja)	2003-03-25
IL148806A (en)	2010-06-16
BRPI0014722B1 (pt)	2019-09-24
PT1224195E (pt)	2005-07-29
CN1407990A (zh)	2003-04-02

Legal Events

Date	Code	Title	Description
2014-05-12	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ASTRAZENECA AB, SE
2020-11-09	MK1K	Patent expired